Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of 99mTc-rhAnnexin V-128 in RA and AS
NCT02328027Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of technetium-tc99m-labeled annexin a5 in rheumatoid arthritis (RA), ankylosing spondylitis (AS), sponsored by Advanced Accelerator Applications. Started Dec 2014; status: terminated.
02
Drugs
technetium-tc99m-labeled annexin a5
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02328027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328027.